With one million new cases of heart failure diagnosed each year, this revolutionary new bathroom product makes it easy for hospitals to monitor patients with this condition from their own homes.
A WC-based cardiovascular monitoring system, created by a team of researchers from the Rochester Institute of Technology, aims to reduce the readmission rates of patients with congestive heart failure.
Conducted by the FDA approval process of the research firm Heart Health Intelligence, it was purchased by hospitals and issued to heart failure patients after discharge. The toilet seats are equipped to measure the electrical and mechanical activity of the heart and can monitor the heart rate, blood pressure, oxygenation in the blood as well as the weight and stroke volume of the patient, ie the amount of blood cells at each heart rate to step. Algorithms analyze the data, and in practice, advanced providers will point out a worsening of the condition. A report is forwarded to cardiologists who then decide if surgery is required.
LOOK : Following the Success of the First 3D Printed House in the US, 50 More Homes Are Built for Poor Families  Nicholas Conn, a postdoctoral fellow at RIT, is the founder and CEO of Heart Health Intelligence Part of the university team that developed the toilet seats and published the studies to his success.
"Usually within 30 days of discharge from the hospital. 25 percent of patients with congestive heart failure will resume, "said Conn. After 90 days of hospitalization, 45% of patients are resumed – and the Centers for Medicare and Medicaid Services penalize hospitals for the recovery of patients due to heart failure.  Conn, the company's chief executive officer, further stated that the mere reimbursement of 150 patients using the national average for readmission rates alone is approximately $ 500,000 per year, as the total cost of care for 150 patients With own monitored toilet seats less than half that amount, hospitals tend to use the lifesaving lots.
MORE : Bedside Bioprinter May Soon burn patient cells to print out new skin directly on wounds  According to Conn, who has received three grades of RIT, the system will catch up with worsening conditions before patients even realize they are symptomatic, and through rapid data analysis, interventions can be as simple as a drug exchange or a short office visit rather than inclusion in the hospital.
HHI, the beginning of the year It came to RIT's Venture Creations incubator, now focusing on moving the product forward. The team is instrumental in creating grants for additional funding and networks. Human tests and preclinical studies are in full swing. Conn and his team are working to approve the product at the FDA and roll it out nationwide.
(Source: Rochester Institute of Health)
Do not waste the Good News: Share it with your friends through social media …